Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol 2023;29(Suppl):S286-S301. Published online December 28, 2022
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Countries, both for end stage liver disease and hepatocellular carcinoma. NAFLD/non-alcoholic steatohepatitis (NASH) is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.
Citations
Citations to this article as recorded by
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2026; 32(2): 104. CrossRef
Deep learning-enhanced quantitative evaluation of hepatic ischemia–reperfusion injury and steatosis via near-infrared hyperspectral imaging Zichen Wang, Zhan Qu, Chen Chen, Jian Du, Jian Zhang, Tao Li, Jianhua Shi, Chun Zhang, Jianwen Lu, Min Tian, Lu Lu, Boyan Tian, Zhen Zhao, Fan Mu, Lexuan Xu, Xin Zhang, Yimeng Wang, Cuiping Yao, Hao Sun, Yi Lyu, Bo Wang, Liangshuo Hu International Journal of Surgery.2026; 112(5): 11274. CrossRef
Rehabilitation challenges and enablers for exercise in post-liver transplant patients with metabolic syndrome: a qualitative study Mingyan Shen, Zuxin Shi, Yanping Shen, Pengxia Wan, Xiaoxiao Zhu BMC Nursing.2026;[Epub] CrossRef
Effectiveness of nutrition education program and omega-3 supplementation on body weight, liver enzyme, lipid profile among non-alcoholic fatty liver disease patients Dilkhosh Shamal Ramadhan, Ibrahim Hasan Mustafa BMC Nutrition.2026;[Epub] CrossRef
Liver transplantation in Japan: Achievements, limitations, and future perspectives Yasuhiko Sugawara BioScience Trends.2026;[Epub] CrossRef
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019 Jacob Romano, Jessica Burnside, Giada Sebastiani, Alnoor Ramji, Keyur Patel, Mark Swain, Sahar Saeed Annals of Hepatology.2025; 30(1): 101757. CrossRef
Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche Advances in Nutrition.2025; 16(3): 100375. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu Biomolecules.2025; 15(2): 163. CrossRef
Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma Marwan Alsaqa, Leandro Sierra, Ana Marenco-Flores, Ximena Parraga, Romelia Barba, Daniela Goyes, N. Begum Ozturk, Michael P. Curry, Alan Bonder, Behnam Saberi European Journal of Gastroenterology & Hepatology.2025; 37(4): 497. CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge Anil Chandra Anand, Dibyalochan Praharaj Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation” Soon Kyu Lee, Jong Young Choi Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review Omaira Valencia, Carolina López, Esteban Vanegas-Duarte, Carolina Fillizola, Diana Fernanda Bejarano Ramírez, Nicolás Andrés Cortés Mejía, Alonso Vera Torres, Kevork M. Peltekian Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates Carme Ginard, Giulia Pagano, Salvatore Brugaletta, Annabel Blasi, Marta Sánchez-Ric, Ander Regueiro, Roger Pujol, Sergio Rodriguez-Tajes, Pablo Ruiz, Jordi Colmenero, Gonzalo Crespo JHEP Reports.2025; 7(7): 101428. CrossRef
The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e58. CrossRef
MAFLD as a Cardiovascular Risk Factor: An Extended Retrospective Study with a Control Group Małgorzata Szymala-Pędzik, Marcin Piersiak, Maciej Pachana, Karolina Lindner-Pawłowicz, Wioletta Szczepaniak, Małgorzata Sobieszczańska Journal of Clinical Medicine.2025; 14(12): 4181. CrossRef
Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis O. O. Karshina, I. S. Sabirov Meditsinskiy sovet = Medical Council.2025; (8): 72. CrossRef
Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease? Renata Zatta, Luana S da Silva, Guilherme Felga, Carolina FMG Pimentel World Journal of Hepatology.2025;[Epub] CrossRef
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D. Vargas, Arjun Jayaswal Journal of Medical Economics.2025; 28(1): 1370. CrossRef
Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan Asma Shabbir, Ambrina Khatoon, Zaigham Abbas, Sucheta Srivastava, Talat Mirza Medical Sciences.2025; 13(3): 178. CrossRef
Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study Young Bin Cho, Kyoung Sik Park Biomedicines.2025; 13(9): 2250. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
A Multi-Modal Deep Fusion Network: Enhancing Graft Survival Prediction in Non-Alcoholic Fatty Liver Disease Patients Prior to Liver Transplantation Devi Rajeev, S Remya, Anand Nayyar IEEE MultiMedia.2025; 32(4): 68. CrossRef
Investigating the Effect of Two Types of Aerobic Exercise on SIRT1 and AMPK Gene Expression Regulation in an Animal Model of Non-Alcoholic Fatty Liver Disease Masoumeh Sadat Foroughi Rahaghi, Lida Moradi, Bahram Abedi, Mohammad Ali Azarbaijani Journal of Shahrekord University of Medical Sciences.2025; 27(4): 192. CrossRef
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey Jeannette Widmer, Janina Eden, Fariba Abbassi, Roberta Angelico, Fabian Rössler, Beat Müllhaupt, Philipp Dutkowski, Marco Bueter, Andrea Schlegel Liver International.2024; 44(2): 566. CrossRef
Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing Shuxuan Li, Yao Zhi, Wentao Mu, Mingqian Li, Guoyue Lv European Journal of Pharmacology.2024; 964: 176300. CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic Arghya Samanta, Moinak Sen Sarma World Journal of Hepatology.2024; 16(4): 511. CrossRef
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru Biomarker Research.2024;[Epub] CrossRef
Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali Journal of Liver Transplantation.2024; 15: 100228. CrossRef
Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease Michael Sun, Vincent J Yao, Aivi A Rahman, Kevin Liu, Saud Rehman, Amber Sun, Alan C Yao Cureus.2024;[Epub] CrossRef
Recent trends and new developments in liver transplantation Yasuhiko Sugawara, Taizo Hibi BioScience Trends.2024; 18(3): 206. CrossRef
Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice Guanliang Chen, Yanwen Yu, Yuqin Zhu, Mayumi Nagashimada, Yajiao Wang, Naoto Nagata, Liang Xu Endocrinology.2024;[Epub] CrossRef
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan Metabolism and Target Organ Damage.2024;[Epub] CrossRef
The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes A. Yu. Ishchenko, M. Yu. Galushko, I. G. Bakulin Meditsinskiy sovet = Medical Council.2024; (15): 146. CrossRef
Cardio-metabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight Svetlana V. Turkina, Mikhail E. Statsenko, Irina A. Tyshchenko, Marina N. Titarenko, Marina A. Kosivtsova, Elena E. Gorbacheva Journal of Volgograd State Medical University.2024; 21(3): 109. CrossRef
Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila Heliyon.2024; 10(22): e40217. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines Soon Kyu Lee Annals of Liver Transplantation.2024; 4(2): 40. CrossRef
Post-transplant complications in alcohol- and metabolic-associated steatotic liver disease Shekhar Singh Jadaun, Sanjiv Saigal Metabolism and Target Organ Damage.2024;[Epub] CrossRef
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease Byeong Geun Song, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 411. CrossRef
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui, Xiangyu Zhong Frontiers in Medicine.2023;[Epub] CrossRef
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients Simone Di Cola, Giulia Cusi, Lucia Lapenna, Jakub Gazda, Stefano Fonte, Marco Mattana, Gianluca Mennini, Patrizio Pasqualetti, Manuela Merli, Xingshun Qi Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1. CrossRef
Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, María José Domper-Arnal, Sandra García-Mateo, Alberto Lué Nutrients.2023; 15(15): 3487. CrossRef
New Developments and Challenges in Liver Transplantation Amjad Khalil, Alberto Quaglia, Pierre Gélat, Nader Saffari, Hassan Rashidi, Brian Davidson Journal of Clinical Medicine.2023; 12(17): 5586. CrossRef
Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma Sameer A. Khan, Fasih A. Ahmed, Muhammad S. Hafeez, Lawrence R. Feng, Abhinav Seth, Yong K. Kwon, Hassan Aziz Journal of Surgical Oncology.2023; 128(8): 1320. CrossRef
First
Prev
